![Adam Levy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 107 440 $ in data 31/05/2026
Adam D.
Levy is currently Director at Vesselon, Inc. and will be Chief Financial Officer at Acrivon Therapeutics, Inc. starting in 2025.
Former roles include Executive Director-Investor Relations at Gilead Sciences, Inc. from 2016 to 2020, EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc. in 2021, Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc. from 2021 to 2022, and Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc. from 2022 to 2023.
Education includes an MBA from Kellogg School of Management and undergraduate studies at the University of Illinois At Urbana–Champaign.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 18/05/2026 | 67.150 ( 0,16% ) | 107 440 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/04/2025 |
Vesselon, Inc.
 Vesselon, Inc. Medical SpecialtiesHealth Technology Develops a portable ultrasound device for brain stroke treatment | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | 01/01/2023 |
| TURG POIN | Contatto Relazioni con gli Investitori | 01/01/2022 |
| ALAUNOS THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 31/12/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2020 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage structure-based drug design company for discovery and development of precision medicines for cancer and other diseases | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Develops a portable ultrasound device for brain stroke treatment | Health Technology |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
 Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Acrivon Therapeutics, Inc.
 Acrivon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops and sells precision oncology medicines | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
